Press Releases

Date Title
Toggle Summary Kura Oncology to Host Investor Day on November 16, 2017
SAN DIEGO , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will host an Investor Day on Thursday, November 16, 2017 , from 8:30 a.m.
Toggle Summary Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Management to host webcast and conference call today at 4:30 p.m. ET SAN DIEGO , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported third quarter 2017
Toggle Summary Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
SAN DIEGO , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that four abstracts relating to the Company’s lead product candidate, tipifarnib, have been
Toggle Summary Kura Oncology to Report Third Quarter 2017 Financial Results
SAN DIEGO , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2017 financial results after the close of U.S.
Toggle Summary Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patients Menin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO , Oct. 28, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the
Toggle Summary Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCC Tipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one year Registration-enabling study of tipifarnib in HRAS mutant HNSCC planned for 2018 SAN DIEGO , Oct.
Toggle Summary Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
SAN DIEGO , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Toggle Summary Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
Four of the first six HRAS mutant HNSCC patients enrolled on study achieve confirmed RECIST partial responses Durable responses greater than one year observed SAN DIEGO , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical stage biopharmaceutical company focused on the
Toggle Summary Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference
SAN DIEGO , Aug. 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will participate in a
Toggle Summary Kura Oncology Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Aug. 10, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a